Latest News

 

<< Previous Page  Next Page >>

Munroe Regional Medical Center Performs 100th TIF Procedure
Friday, May 8, 2009
Redwood City, CA (May 7, 2009) – EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that Munroe Regional Medical Center, in Ocala, Florida, has performed 100 TIF (Transoral Incisionless Fundoplication) procedures for the treatment of chronic acid reflux, or gastroesophageal reflux
 
EndoGastric Solutions Finalizes Expansion of Commercial Organization
Friday, April 17, 2009
Redwood City, CA (April 17, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced completion of an important sales and marketing expansion to support its growing commercialization success. EGS also announced the appointment of Tom Dempsey as Vice President of U.S. Sales, effective
 
SAGES Issues Position Statement Supporting Endolumenal Therapies for GERD and Obesity
Friday, April 10, 2009
Redwood City, CA (April 10, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced its support of SAGES (the Society of American Gastrointestinal and Endoscopic Surgeons) Position Statement on Endolumenal Therapies for Gastrointestinal Diseases including GERD and Obesity published
 
Published Study Supports Two-Year Safety and Efficacy of Incisionless TIF Surgery for the Treatment of GERD
Thursday, March 26, 2009
Redwood City, CA (March 26, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced publication of a two-year study of TIF (Transoral Incisionless Fundoplication) procedure for the surgical treatment of GERD (gastroesophageal reflux disease) confirming the procedure’s safety and
 
EndoGastric Solutions Announces Shipping Over 700 New EsophyX2 Devices
Friday, February 20, 2009
Redwood City, CA (February 20, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that over 700 EsophyX2 devices have shipped worldwide. The next generation of its innovative EsophyX® device, EsophyX2 facilitates the creation of a robust, tight antireflux valve with the TIF®2
 
27 New Medical Centers Join Growing List of U.S. Sites Performing NOS EsophyX or StomaphyX Procedures
Wednesday, January 28, 2009
Redwood City, CA (January 28, 2009) — EndoGastric Solutions® (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that 15 new U.S. medical centers performed their first TIF® (Transoral Incisionless Fundoplication) surgical procedures for the treatment of GERD (Gastroesophageal Reflux Disease) last quarter
 
EGS Launches 12 New Incisionless Orifice Surgery Centers in September
Monday, October 20, 2008
Redwood City, CA (October 17, 2008) — EndoGastric Solutions® (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that five new surgery centers performed their first TIF® (Transoral Incisionless Fundoplication) surgical procedures for the treatment of GERD (Gastroesophageal Reflux Disease). The procedures were
 
EGS Launches Four New EsophyX TIF Procedure Sites in August
Tuesday, September 9, 2008
Redwood City, CA (September 9, 2008) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that University of California Irvine (UCI) Medical Center of Orange, CA; Memorial Hermann Hospital of Houston, TX; Lenox Hill Hospital, New York, NY, and CentraState Medical Center of Freehold, NJ,

 

<< Previous Page  Next Page >>

 

Request Info button

 

NP01937-01A